25K0 Stock Chart & Stats
€5.90
-€0.05(-0.84%)
At close: 4:00 PM EDT
€5.90
-€0.05(-0.84%)
Day’s Range― - ―
52-Week Range€3.18 - €9.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€37.72M
Enterprise Value€277.69
Total Cash (Recent Filing)€90.85M
Total Debt (Recent Filing)€230.87M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.84
Shares Outstanding22,662,943
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.27
Price to Sales (P/S)0.55
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.08Price Target Upside3.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.56
Revenue Forecast (FY)€121.52M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~96% gross margins indicate very strong product-level economics for XPOVIO, providing durable contribution margin to fund R&D and commercial scale. This structural profitability at the gross line supports long-term leverage if sales grow and helps insulate unit economics from moderate price pressure.
Phase III SENTRY Efficacy And OS SignalRobust SENTRY spleen-response and an overall survival signal provide durable clinical differentiation and a potential disease‑modifying claim. These high-quality Phase III data materially strengthen regulatory and commercial positioning for selinexor+ruxolitinib in myelofibrosis and support a credible pathway to broader adoption and label expansion.
Lower Debt And Near-term FinancingMaterial reduction in reported debt and a completed ~$50M financing improve near-term solvency and reduce refinancing stress. This stronger capital structure increases the probability management can execute pending regulatory filings and commercial launches without immediate distress, lengthening runway to key catalysts.
Bears Say
Persistent Negative Cash FlowOngoing negative operating and free cash flow (~-$59M TTM) reflect a structural cash burn that will require recurring financing or material revenue scale to correct. Persistent outflows limit strategic optionality, raise dilution risk, and constrain the company's ability to sustain high R&D and commercial investments without external capital.
Deeply Negative Equity BaseSubstantially negative shareholders' equity (~-$266M TTM) materially weakens financial flexibility and increases going-concern sensitivity. This structural capital deficiency makes debt financing or non-dilutive options harder to obtain and heightens the likelihood of dilutive equity or strategic transactions under adverse scenarios.
Short Cash Runway And Financing NeedA runway only into late Q3 2026 forces dependence on near-term financing, milestone receipts, or strategic deals. That timing elevates execution risk: management may need to pursue dilutive financing or strategic transactions before key regulatory clarity, potentially compromising long‑term shareholder outcomes and operational independence.
Karyopharm Therapeutics News
25K0 FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was €3.18 and its highest was €9.25 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is €37.72M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 88 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Currently, no data Available
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 22,662,943 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in DE:25K0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.08 (3.07% Upside)
€6.08 (3.07% Upside)
Blogger Sentiment
Neutral
DE:25K0 Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 11%
Bearish news 89%
Bearish news 89%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.90%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
25K0 Company Deck
25K0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong clinical momentum and significant near-term catalysts: compelling Phase III SENTRY results with a statistically robust spleen response and an intriguing overall survival signal, completed enrollment in EC042 with prior SIENDO data showing deep and durable PFS benefit, ASCO presentation and planned mid-2026 manuscript, and quarter-over-quarter revenue improvement driven by gross-to-net gains. These positives are tempered by competitive pressure that reduced underlying demand for XPOVIO, gross-to-net volatility, continued net losses and high operating spend, and a limited cash runway into late Q3 2026 that may necessitate additional financing or milestone events. Regulatory timing and the need for further data granularity (e.g., deaths attribution) add some near-term uncertainty. On balance, the clinical and strategic highlights are material and potentially value-creating, though execution and financing risks remain.View all DE:25K0 earnings summaries25K0 Stock 12 Month Forecast
Average Price Target
€6.08
▲(3.07% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―